[ad_1]
LONDON – The World Health Organization says Congo has launched the first-ever trial to test the efficacy and safety of four experimental Ebola drugs, the first time scientists have compared such treatments directly.
In a statement released Monday, the US health agency described the initiative as "a gigantic step" that "would shed light on what works best". To date, more than 160 people have been treated with these experimental drugs. Patients will no longer be treated differently than before, but scientists will now have a clinical trial framework to collect data.
The drugs tested are three antibody treatments and one antiviral. So far, in the current epidemic in Congo, there have been 346 confirmed cases of Ebola and 175 deaths.
The epidemic has been undermined by security concerns, with some health workers having been attacked by rebels.
r n {% endblock%} "}," start ":" https: / / users.startribune.com / placement / 1 / environment / 3 / limit-signup-optimizely / start "}, {" id ":" limit-registration "," number ": 12," action ":" ignore "," mute ": true," action_config ": {" template ":" {% extends " "%} {% block heading_text%} You have read your 10 free articles for this 30 day period. Sign up now to benefit from local coverage that you will not find anywhere else, special sections and your favorite columnists. StarTribune puts Minnesota and the world at your fingertips. {% endblock%} {% last block}} {{parent ()}} r {# limits the number of Krux pixels from https: / / www.squishlist. com / strib / customshop / 328 / #} r n
r n r n {% endblock%} "}," start ":" https: / / users.startribune.com / placement / 1 / environment / 3 / limit-signup / start "} , {"id": "meter-desktop-331", "count": 10, "action": "ignore", "mute": false, "action_config": false, "start": "https: / /users.startribune.com \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ ":" https: / / users.startribune.com / placement / 1 / environment / 3 / PDA991499opt / start "}, {" id ":" limit "," count ": 8, "action": "inject", "mute": false, "action_config": {"template": "
r n r n
r n
r n t
r n r n
r n
r n
r n
r n
r n "}," start ":" https: / / users.startribune.com / placement / 1 / environment / 3 / limit / start "}, {" id ":" nag "," count ": 7," action ":" lightbox "," mute ": true," action_config ": {" height ": null," width ":" 630px "," redirect_on_close ": null," template ":" {% extend "shell "%} {% the sub-styles of blocks%} r n
{% endblock%} {% blocking page%} {{{limit - count-1}} r n {{form.flow_form_open ({nextAction: 'firstSlide', null, null, _top '}} {{form.btn (& # 39; # 39; Save Now}} { form.flow_form_close ()}} r n r n
r n r n u2022 r n }}){kind=logo}
#} r n
You still have {{limit - count - 1}} items
r n
r n r n u2022 u2022 n n n n r n
r n
r n
r n  }})
r n
More than 70% off!
r n
 }}){kind=logo}
r n r n
r n
99 u002 for the first 4 weeks
{{form.flow_form_open ({nextAction: 'firstSlide', null, null, _top '}} { form.button (& # 39; Save Now & # 39;; & # 39;; btn nag-btn & nbsp; & nbsp; & nbsp; & nbsp; & nbsp; & nbsp; & nbsp; & nbsp; & nbsp; & nbsp; & nbsp;}}}
r n
{% endblock%} {% last block}} {{parent ()}} r n r n {% endblock%} "}," start ":" https: / / users.startribune.com / placement / 1 / environment / 3 / nag / start "}, { "id": "x", "count": 4, "action": "ignore", "mute": true, "action_config": false, "start": "https: / / users.startribune.com / placement / 1 / environment / 3 / x / start "}, {" id ":" multiple startup "," account ": 3," action ":" fly_in "," mute ": true , "action_config": {"location": "bottom_left", "slide_direction": "bottom", "group_id": null, "display_delay": "0", "collapse_delay": "10", "template": "
r n
"}," start ":" https: / / users.startribune.com / placement / 1 / environment / 3 / multi-start / start "}]};
[ad_2]
Source link
